Alimera Sciences
Acquired- Employees
- 51–200
- Business Model
- B2B
- Website
- alimerasciences.com
- Last Round
- Venture RoundFeb 2014
- Rounds
- 2
About
Alimera Sciences was a global pharmaceutical company focused on diseases affecting the retina. Its flagship product, ILUVIEN, is a sustained-release intravitreal implant approved for diabetic macular edema and non-infectious uveitis. The company served patients and physicians across the US and international markets before being acquired by ANI Pharmaceuticals in September 2024.
Summary
Its most recent funding was a Venture Round round in Feb 2014. Investors include ANI Pharmaceuticals, Palo Alto Investors and Sofinnova Partners.
Tech & App Stack
4 technologies & apps tracked
Create a free account to track companies, build lists, and unlock premium data like the full tech & app stack.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Jun 2024
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
